TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to “Sell” at Wall Street Zen

TuHURA Biosciences (NASDAQ:HURA) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

HURA has been the topic of a number of other research reports. Citizens Jmp started coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued a “market outperform” rating and a $9.00 target price on the stock. Citigroup started coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued an “outperform” rating on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Tuesday, April 21st. Finally, Rodman & Renshaw started coverage on shares of TuHURA Biosciences in a research note on Wednesday, April 15th. They issued a “buy” rating on the stock. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, TuHURA Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

TuHURA Biosciences Trading Down 3.8%

Shares of TuHURA Biosciences stock opened at $2.26 on Friday. The company has a fifty day moving average price of $2.26 and a 200 day moving average price of $1.61. TuHURA Biosciences has a twelve month low of $0.41 and a twelve month high of $3.90. The stock has a market cap of $143.92 million, a price-to-earnings ratio of -3.70 and a beta of -0.01.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Analysts forecast that TuHURA Biosciences will post -0.56 earnings per share for the current year.

Institutional Investors Weigh In On TuHURA Biosciences

Several hedge funds have recently made changes to their positions in HURA. Virtu Financial LLC purchased a new stake in shares of TuHURA Biosciences in the 3rd quarter valued at approximately $26,000. JPMorgan Chase & Co. purchased a new stake in shares of TuHURA Biosciences in the 2nd quarter valued at approximately $27,000. Wells Fargo & Company MN lifted its position in shares of TuHURA Biosciences by 109.0% in the 4th quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock valued at $29,000 after acquiring an additional 19,931 shares in the last quarter. Invesco Ltd. purchased a new stake in shares of TuHURA Biosciences in the 2nd quarter valued at approximately $30,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of TuHURA Biosciences in the 4th quarter valued at approximately $30,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.